Chimeric antigen receptor (CAR) T cell therapies are ex vivo manufactured cellular products that have been useful in the treatment of blood cancers and solid tumors. The quality of the final cellular product is influenced by several amenable factors during the manufacturing process. This review discusses several of the influences on cell product phenotype, including the raw starting material, methods of activation and transduction, and culture supplementation.
CITATION STYLE
Schwab, R. D., Bedoya, D. M., King, T. R., Levine, B. L., & Posey, A. D. (2020). Approaches of T Cell Activation and Differentiation for CAR-T Cell Therapies. In Methods in Molecular Biology (Vol. 2086, pp. 203–211). Humana Press Inc. https://doi.org/10.1007/978-1-0716-0146-4_15
Mendeley helps you to discover research relevant for your work.